GeoVax Labs, Inc. (NASDAQ: GOVX) is engaged as a biotechnology company, which is focused on the research and development of immunotherapies and vaccines to treat infectious diseases and cancers. Shares of the biotech company are rallying 16% through early trading on Tuesday, May 24, 2022. Over the past three months, GeoVax has seen average daily volume of 4.25 million shares. However, volume of 76.18 million shares or dollar volume of around $204.16 million, has already exchanged hands through early trading.
Shares of GeoVax are gaining after the company announced that it has been issued a Notice of Allowance for a patent application entitiled “Compositions and Methods for Generating an Immune Response to a Tumor Associated Antigen,” from the Chinese Patent Office. The patent provides coverage for the company’s vector platform for expressing tumor-based antigens in virus-like particles from a Modified Vaccinia Ankara viral vector and encompass GeoVax’s Mucin 1 immunotherapy candidate.
GeoVax utilizes its vaccine platform to treat abnormal, aberrantly glycosylated forms of the cell surface-associated Mucin 1 protein, which is linked to numerous cancers such as breast, colon, ovarian, prostate, lung, and pancreatic. Early initial results with its vaccine-based immunotherapy candidates have been positive and GeoVax has recently launched an IND-enabled animal study at the University of North Carolina at Charlotte. The company strongly believes its vector platform is in a great position for the development of therapeutic cancer vaccines.
David Dodd, GeoVax President and CEO, commented, “This patent allowance complements the previously issued U.S. Patent No. 11278607, demonstrating the global importance of this technology, and adding to our growing portfolio of wholly owned, co-owned, and in-licensed intellectual property, which now stands at over 70 granted or pending patent applications spread over 20 patent families. GeoVax is committed to advancing meaningful cancer immunotherapies towards improving the lives of patients worldwide.”
Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/
